Peregrine Pharmaceuticals, Inc. (PPHM) Reaches Agreement With FDA on a Phase III Trial Design for Bavituximab in Second-Line Non-Small Cell Lung Cancer
5/20/2013 11:41:59 AM
More...
|
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab
4/30/2013 11:24:05 AM
More...
|
Data Presented at American Association for Cancer Research Annual Meeting Support Targeted Immune Reactivation Mechanism and Potential of Peregrine Pharmaceuticals, Inc. (PPHM)'s Bavituximab in Solid Tumor Therapy
4/10/2013 11:57:19 AM
More...
|
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Three Abstracts Accepted for Presentation at American Association for Cancer Research 2013 Annual Meeting
4/2/2013 9:20:38 AM
More...
|
Peregrine Pharmaceuticals, Inc. (PPHM) Reports Third Quarter Fiscal Year 2013 Financial Results and Recent Developments
3/13/2013 8:26:59 AM
More...
|
Peregrine Pharmaceuticals, Inc. (PPHM) to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013
3/6/2013 9:33:29 AM
More...
|
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Participation at Upcoming Investor Conferences
2/27/2013 10:47:27 AM
More...
|
Peregrine Pharmaceuticals, Inc. (PPHM) Reports Positive Results From Revised Lung Cancer Trial Data
2/19/2013 7:34:58 AM
More...
|
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic Cancer
2/13/2013 9:52:48 AM
More...
|
Peregrine Pharmaceuticals, Inc. (PPHM) Provides Update on the Internal Review of Its Phase II Second-Line Non-Small Cell Lung Cancer Trial
1/7/2013 10:20:00 AM
More...
|
|